# Nurix Therapeutics Swings to $549.8M Q3 Profit on Roche License Revenue

- URL: https://stocks.freetheai.org/news/nurix-therapeutics-swings-to-549-8m-q3-profit-on-roche-license-revenue-d103a7
- Published: 2026-10-13T10:31:00Z
- Category: earnings; sentiment: bullish; impact: high
- Symbols: [NASDAQ:NRIX](https://stocks.freetheai.org/symbols/NASDAQ-NRIX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Nurix Therapeutics, Inc. (NRIX) reported a significant financial turnaround for the third quarter of 2026, generating $673.1 million in revenue compared to $7.9 million in the same period last year. Net income reached $549.8 million, or $4.73 per diluted share, swinging from a net loss of $86.4 million, or $1.03 per share, a year earlier.

The quarter's dramatic jump in revenue was primarily driven by the recognition of $653.2 million in license revenue from partner Roche. The influx of capital shifts the company's revenue mix heavily toward collaboration fees. Nurix has received $1.2 billion in total payments to date across its major pharmaceutical partnerships, which include Roche, Gilead, Sanofi, and Pfizer, with potential milestone and royalty payments reaching up to $7.2 billion.

Looking ahead, Nurix is reallocating resources by stopping development on zelebrudomide to focus on key clinical programs. The company has advanced bexobrutideg into a global Phase 3 trial and dosed the first patient in Phase 1b expansion studies for NX-1607. Operating costs in research, development, and administration are rising to support late-stage clinical trials and manufacturing scaling, with costs shared under its agreement with Roche.

## Key points

- Nurix Therapeutics posted Q3 2026 revenue of $673.1 million, up from $7.9 million in the year-ago quarter.
- Net income reached $549.8 million, or $4.73 per diluted share, swinging from an $86.4 million loss a year earlier.
- Performance was powered by recognizing $653.2 million in license revenue from collaboration partner Roche.
- Clinical focus shifts to bexobrutideg Phase 3 trials and NX-1607 while development of zelebrudomide was ended.

## Questions and answers

### What were Nurix Therapeutics' Q3 2026 earnings results?

Nurix Therapeutics reported Q3 2026 net income of $549.8 million, or $4.73 per diluted share, on total revenue of $673.1 million.

### Why did Nurix Therapeutics revenue increase significantly in Q3 2026?

The revenue growth was primarily driven by recognizing $653.2 million in license revenue under its collaboration agreement with Roche.

### Which clinical programs is Nurix Therapeutics prioritizing?

Nurix is advancing bexobrutideg into global Phase 3 trials and expanding Phase 1b studies for NX-1607, while discontinuing development of zelebrudomide.